Biogen Alzheimer drug fails to meet mid-stage trial goal
Biogen announced on Thursday that its Alzheimer’s drug did not meet the main goal of a mid-stage trial. The results follow the completion of the study phase.
Xurve View
Insights:
Xurve View
BIOGEN INC said its Alzheimer's drug did not meet the main goal of a mid-stage trial. The setback affects the company's neurology portfolio expansion. Drug failures can shift investor focus to other pipeline candidates.
